IM Cannabis (NASDAQ:IMCC – Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.03) per share for the quarter.
IM Cannabis (NASDAQ:IMCC – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.67. IM Cannabis had a negative net margin of 26.46% and a negative return on equity of 97.26%. The firm had revenue of $10.78 million for the quarter, compared to analysts’ expectations of $9.62 million. On average, analysts expect IM Cannabis to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
IM Cannabis Price Performance
Shares of NASDAQ IMCC opened at $1.97 on Thursday. IM Cannabis has a fifty-two week low of $1.13 and a fifty-two week high of $8.10. The company has a 50 day simple moving average of $2.21 and a two-hundred day simple moving average of $2.85. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.52 and a current ratio of 0.69. The company has a market capitalization of $4.39 million, a price-to-earnings ratio of -0.48 and a beta of 0.45.
IM Cannabis Company Profile
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands.
Read More
- Five stocks we like better than IM Cannabis
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
- Market Cap Calculator: How to Calculate Market Cap
- Atlassian Is Up +60% in Three Months—What’s Causing the Rally?
- What are earnings reports?
- 2 Reasons To Like Coinbase After The Election, 1 to Still Avoid
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.